<DOC>
	<DOC>NCT00125892</DOC>
	<brief_summary>This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.</brief_summary>
	<brief_title>A Study of Duloxetine in the Treatment of Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Meet criteria for primary fibromyalgia syndrome as defined by the American College of Rheumatologists Treatment with a monoamine oxidase inhibitor within 14 days prior to Visit 2 or the potential need to take within 5 days after discontinuation from the study. Any patients judged by their physicians to be at serious suicidal risk. Have uncontrolled narrowangle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>